A recent subanalysis from the HF-ACTION study, however, showed no differential response of MRAs in patients with Gal-3 below or above the FDA-cleared cutpoint of 17.8 ng/mL [23]. The gene discussed is LGALS3; the disease is hydrops fetalis.